Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
With
Ceruvia Lifesciences
The number of arms reflects the design of the enhanced blinding method. The final enrollment number reflects the number of subjects participating in study procedures.
Age
21–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of migraine headache per ICHD-3beta criteria
Typical pattern of migraine attacks with approximately two migraines or more weekly
Attacks are managed by means involving no more than twice weekly triptan use
Age 21 to 65
You may not be if
Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)
Axis I psychotic disorder in first degree relative
Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology
Pregnant, breastfeeding, lack of adequate birth control
History of intolerance to psilocybin, LSD, or related compounds
Drug or alcohol abuse within the past 3 months (excluding tobacco)
Urine toxicology positive to drugs of abuse
Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days
Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks
Use of antidepressant medication (i.e. TCA, MAOI, SSRI) in the past 6 weeks
Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks
Clareo Health | Psilocybin for the Treatment of Migraine Headache
